#United States #South San Francisco #Rigel Pharmaceuticals #Arvinas #VEPPANU

Major Development in Breast Cancer Treatment: Rigel Pharmaceuticals Finalizes Licensing Agreement for VEPPANU

In a significant stride towards combatting advanced forms of breast cancer, Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has successfully concluded its licensing agreement for VEPPANU™ (vepdegestrant). This development follows the early termination of the waiting period mandated by the Hart-Scott Rodino Antitrust Improvements Act of 1976, along with the fulfillment of other customary closing conditions. The deal solidifies Rigel's collaboration with Arvinas, Inc. and Pfizer Inc., paving the way for the commercial launch of VEPPANU, which is expected to hit the market in August 2026.

What is VEPPANU?

VEPPANU is specifically designed for adults battling estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer with mutations in the estrogen receptor 1 (ESR1) gene. This advanced therapy is crucial for patients who have experienced disease progression following at least one line of endocrine therapy, as confirmed by tests approved by the U.S. Food and Drug Administration (FDA).

The agreement became effective on June 11, 2026, following Rigel's upfront payment of $70 million, divided between Arvinas and Pfizer, which aligns with the terms set forth in the licensing contract.

Safety and Efficacy Insights

VEPPANU is expected to bring a new dimension to treatment options for patients suffering from this specific type of advanced breast cancer. Nevertheless, as with many advanced therapeutics, there are important safety considerations:

• - QTc Interval Prolongation: It is essential that clinicians monitor the QTc interval closely, as VEPPANU can prolong this interval in some patients. Regular ECG assessments are advised.
• - Embryo-Fetal Toxicity: Women who are pregnant or those who can become pregnant should be fully informed of the potential risks associated with this medication. It is recommended that effective contraceptive measures be used during and up to two weeks after treatment.

Adverse reactions have been reported in a small percentage of users, with the most common side effects including decreased white blood cell counts, increased liver enzymes, and fatigue.

Market Insights and Future Prospects

The commercial availability of VEPPANU signifies a pivotal moment not just for Rigel Pharmaceuticals, but for the oncology community at large. As the demand for targeted therapies increases, VEPPANU holds the potential to enhance patient outcomes for those facing challenging forms of breast cancer.

Rigel's commitment to pioneering innovative biotech solutions reflects its core mission of improving patients' lives through novel therapies. Founded in 1996, the company continues to lead in research focused on hematologic disorders and oncology, with VEPPANU being the latest addition to its portfolio of important pharmaceutical advancements.

With rigorous clinical collaborations and a structured approach to launching VEPPANU, Rigel Pharmaceuticals is positioning itself for promising growth in a highly competitive healthcare landscape. The successful rollout of this new treatment can set a benchmark for future innovations in biopharmaceuticals geared toward advanced cancers.

In conclusion, Rigel's licensing agreement with Arvinas and Pfizer for VEPPANU represents not only a strategic business move but also a beacon of hope for patients grappling with advanced breast cancer, highlighting the ongoing quest for groundbreaking cancer therapies in the fight against this devastating disease.